In a new study, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Donald C. Goff, MD, speaks with author Charles L. Raison, MD, from the Usona Institute, about the study, as well as Rachel Yehuda, PhD, Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.